Acasti concludes CaPre versus Lovaza preclinical program
Blood lipids were monitored in two animal models in order to assess and compare the efficacy of CaPre and Lovaza over a 12-week treatment period. Acasti said that
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.